Derma Sciences Reports 2016 Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Derma Sciences (DSCI) Tops Q2 EPS by 16c
August 9, 2016 7:36 AM EDTDerma Sciences (NASDAQ: DSCI) reported Q2 EPS of $0.08, $0.16 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $22.2 million versus the consensus estimate of $22.4 million.
Financial Guidance
Reflecting the acquisition of BioD and the pending sale of its FAD, Derma Sciences is providing the following information and financial... More
